143 related articles for article (PubMed ID: 12670781)
1. Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease?
Grootendorst DC; Gauw SA; Baan R; Kelly J; Murdoch RD; Sterk PJ; Rabe KF
Pulm Pharmacol Ther; 2003; 16(2):115-20. PubMed ID: 12670781
[TBL] [Abstract][Full Text] [Related]
2. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study.
Compton CH; Gubb J; Nieman R; Edelson J; Amit O; Bakst A; Ayres JG; Creemers JP; Schultze-Werninghaus G; Brambilla C; Barnes NC;
Lancet; 2001 Jul; 358(9278):265-70. PubMed ID: 11498212
[TBL] [Abstract][Full Text] [Related]
3. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.
Gamble E; Grootendorst DC; Brightling CE; Troy S; Qiu Y; Zhu J; Parker D; Matin D; Majumdar S; Vignola AM; Kroegel C; Morell F; Hansel TT; Rennard SI; Compton C; Amit O; Tat T; Edelson J; Pavord ID; Rabe KF; Barnes NC; Jeffery PK
Am J Respir Crit Care Med; 2003 Oct; 168(8):976-82. PubMed ID: 12816740
[TBL] [Abstract][Full Text] [Related]
4. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.
Rennard SI; Schachter N; Strek M; Rickard K; Amit O
Chest; 2006 Jan; 129(1):56-66. PubMed ID: 16424413
[TBL] [Abstract][Full Text] [Related]
5. Cilomilast (Ariflo) does not potentiate the cardiovascular effects of inhaled salbutamol.
Murdoch RD; Cowley H; Kelly J; Higgins R; Webber D
Pulm Pharmacol Ther; 2002; 15(6):521-7. PubMed ID: 12493339
[TBL] [Abstract][Full Text] [Related]
6. Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD.
Cazzola M; Santus P; D'Adda A; Pizzolato S; Di Marco F; Centanni S
Pulm Pharmacol Ther; 2009 Jun; 22(3):177-82. PubMed ID: 19038356
[TBL] [Abstract][Full Text] [Related]
7. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.
Giembycz MA
Expert Opin Investig Drugs; 2001 Jul; 10(7):1361-79. PubMed ID: 11772257
[TBL] [Abstract][Full Text] [Related]
8. Bronchodilating effect of combined therapy with ipratropium bromide and ondansetron in patients with COPD.
Pauwels R; Joos GF; Fogarty C; Faiferman I; Hirschberg S; Vessey R; Wouters EF
Pulm Pharmacol Ther; 2008; 21(2):385-92. PubMed ID: 18023600
[TBL] [Abstract][Full Text] [Related]
9. Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD.
Norris V; Ambery C
Pulm Pharmacol Ther; 2013 Oct; 26(5):574-80. PubMed ID: 23524017
[TBL] [Abstract][Full Text] [Related]
10. Cilomilast.
Schachter EN
Drugs Today (Barc); 2006 Apr; 42(4):237-47. PubMed ID: 16703120
[TBL] [Abstract][Full Text] [Related]
11. Effects of cilomilast, a selective phosphodiesterase 4 inhibitor, on esophageal motility and pH, and orocecal and colonic transit: two single-center, randomized, double-blind, placebo-controlled, two-part crossover studies in healthy volunteers.
Houghton LA; Atkinson W; Whorwell PJ; Morris J; Murdoch RD; Cooper SM; Webber DM; Walls CM
Clin Ther; 2006 Apr; 28(4):569-81. PubMed ID: 16750468
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of nebulized levalbuterol in stable COPD.
Datta D; Vitale A; Lahiri B; ZuWallack R
Chest; 2003 Sep; 124(3):844-9. PubMed ID: 12970007
[TBL] [Abstract][Full Text] [Related]
13. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
Balkissoon R; Make B
COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
[TBL] [Abstract][Full Text] [Related]
14. Walking exercise response to bronchodilation in mild COPD: a randomized trial.
Gagnon P; Saey D; Provencher S; Milot J; Bourbeau J; Tan WC; Martel S; Maltais F
Respir Med; 2012 Dec; 106(12):1695-705. PubMed ID: 22999808
[TBL] [Abstract][Full Text] [Related]
15. Cilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease.
Martina SD; Ismail MS; Vesta KS
Ann Pharmacother; 2006 Oct; 40(10):1822-8. PubMed ID: 16985092
[TBL] [Abstract][Full Text] [Related]
16. The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD.
Singh D; Abbott-Banner K; Bengtsson T; Newman K
Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30166326
[TBL] [Abstract][Full Text] [Related]
17. An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease.
Giembycz MA
Br J Clin Pharmacol; 2006 Aug; 62(2):138-52. PubMed ID: 16842388
[TBL] [Abstract][Full Text] [Related]
18. [Effects of salbutamol and ipratropium bromide on arterial blood gases in patients with stable COPD].
Ozdemir T; Geçkin E; Oğüş C; Cilli A
Tuberk Toraks; 2003; 51(2):132-7. PubMed ID: 15143418
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease.
Niewoehner DE; Lapidus R; Cote C; Sharafkhaneh A; Plautz M; Johnson P; Kesten S
Pulm Pharmacol Ther; 2009 Dec; 22(6):587-92. PubMed ID: 19737620
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI.
Zuwallack R; De Salvo MC; Kaelin T; Bateman ED; Park CS; Abrahams R; Fakih F; Sachs P; Pudi K; Zhao Y; Wood CC;
Respir Med; 2010 Aug; 104(8):1179-88. PubMed ID: 20172704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
